Brussels

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer5 trials
• Lung cancer4 trials
• Multiple sclerosis3 trials
• Coronary artery disease2 trials
• Familial hypercholesterolaemia2 trials
• Head and neck cancer2 trials
• Kidney cancer2 trials
• Stroke2 trials
• Aortic stenosis1 trial
• Chronic myeloid leukaemia1 trial
• Epilepsy1 trial
• Gastric and oesophageal cancer1 trial
• and 7 more

Phase

• Phase 311 trials
• Phase 15 trials
• Phase 24 trials
• Phase 2/31 trial

Status

• Completed8 trials
• Active, not recruiting5 trials
• Recruiting4 trials
• Terminated4 trials

Lead sponsor

• Novartis Pharmaceuticals21 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

  NCT06597019· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  NCT06562192· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

  NCT02962414· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis1 recruiting
• Colorectal cancer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Multiple sclerosis1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

  NCT05462873· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

  NCT04129528· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

  NCT04000529· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

  NCT03769168· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

  NCT03798626· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

  NCT03474965· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

  NCT01828112· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source